Annals of Surgical Oncology Sign the Guestbook
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
10.1245/s10434-007-9653-8
Annals of Surgical Oncology 15:547-554 (2008)
© 2008 Society of Surgical Oncology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Ogawa, E.
Right arrow Articles by Tanaka, F.
PubMed
Right arrow Articles by Ogawa, E.
Right arrow Articles by Tanaka, F.

Original Article

Perimembrane Aurora-A Expression is a Significant Prognostic Factor in Correlation with Proliferative Activity in Non-Small-Cell Lung Cancer (NSCLC)

Eiji Ogawa, MD1,2, Kazumasa Takenaka, MD, PhD1, Hiromichi Katakura, MD, PhD1, Masashi Adachi, MD1, Yosuke Otake, MD, PhD1, Yoshinobu Toda, PhD3, Hirokazu Kotani, MD, PhD2,3, Toshiaki Manabe, MD, PhD2, Hiromi Wada, MD, PhD1 and Fumihiro Tanaka, MD, PhD1

1 Department of Thoracic Surgery, Faculty of Medicine, Kyoto University, Kyoto, Japan
2 Laboratory of Anatomic Pathology, Kyoto University Hospital, Kyoto, Japan
3 Center for Anatomical Studies, Kyoto University Graduate School of Medicine, Kyoto, Japan

Correspondence: Address correspondence and reprint requests to: Fumihiro Tanaka, MD, PhD; E-mail: ftanaka{at}kuhp.kyoto-u.ac.jp

Purpose: Aurora-A, also known as STK15/BTAK, is a member of the protein serine/threonine kinase family, and experimental studies have revealed that Aurora-A plays critical roles in cell mitosis and in carcinogenesis. However, no clinical studies on Aurora-A expression in non-small-cell lung cancer (NSCLC) have been reported. Thus, the present study was conducted to assess the clinical significance of Aurora-A status.

Experimental Design: A total of 189 consecutive patients with resected pathologic (p-)stage I-IIIA, NSCLC were retrospectively reviewed, and immunohistochemical staining was used to detect Aurora-A expression.

Results: Aurora-A expression was negative in 31 patients (16.4%); among Aurora-A positive patients, 124 patients showed pure diffuse cytoplasmic Aurora-A expression and the other 34 patients showed perimembrane Aurora-A expression. Perimembrane Aurora-A tumors showed the highest proliferative index (PI) (mean PIs for negative, diffuse cytoplasmic, and perimembrane tumors: 49.2, 41.7, and 63.5, respectively; P < .001). Five-year survival rates of Aurora-A negative, diffuse cytoplasmic, and perimembrane patients were 67.8%, 66.7%, and 47.6%, respectively, showing the poorest postoperative survival in perimembrane patients (P = .033). Subset analyses revealed that perimembrane Aurora-A expression was a significant factor to predict a poor prognosis in squamous cell carcinoma patients, not in adenocarcinoma patients. A multivariate analysis confirmed that perimembrane Aurora-A expression was an independent and significant factor to predict a poor prognosis.

Conclusions: Perimembrane Aurora-A status was a significant factor to predict a poor prognosis in correlation with enhanced proliferative activity in NSCLC.

Key Words: Aurora-A • Lung cancer • Proliferation • Surgery • Prognosis






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the Society of Surgical Oncology.